John McHutchison, MD

Dr. Hutchison retired as president and CEO of Assembly Biosciences Inc. at the end of 2022. Prior to Assembly, he was chief scientific officer and head of research and development at Gilead Sciences. At Gilead, he led the development of a broad range of liver-directed therapies, including he curative HCV antiviral regimens.

  • March 2023

Added to: Tune Therapeutics - Durham, NC

Tune Therapeutics is a biotechnology company pioneering the creation of genetic tuning (epigenomic editing) therapies.